Maravai Lifesciences Holdings Inc Net Assets
Maravai Lifesciences Holdings Inc net assets. Based on the latest financial reports, Maravai Lifesciences Holdings Inc (MRVI) has net assets worth $355.59 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($603.75 Million) and total liabilities ($248.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Maravai Lifesciences Holdings Inc net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $355.59 Million |
| % of Total Assets | 58.9% |
| Annual Growth Rate | 14.1% |
| 5-Year Change | -31.66% |
| 10-Year Change | N/A |
| Growth Volatility | 93.72 |
Net Assets of Maravai Lifesciences Holdings Inc (2018–2025)
Net assets of Maravai Lifesciences Holdings Inc from 2018 to 2025. This chart illustrates how Maravai Lifesciences Holdings Inc's net assets have evolved over time, based on quarterly financial data. See Maravai Lifesciences Holdings Inc balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Maravai Lifesciences Holdings Inc (2018–2025)
The table below shows the annual net assets of Maravai Lifesciences Holdings Inc from 2018 to 2025. For live market cap and overall valuation, see how much is Maravai Lifesciences Holdings Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $372.71 Million | -35.43% |
| 2024-12-31 | $577.21 Million | -26.92% |
| 2023-12-31 | $789.88 Million | -12.74% |
| 2022-12-31 | $905.24 Million | +65.99% |
| 2021-12-31 | $545.36 Million | +252.42% |
| 2020-12-31 | $154.75 Million | +7.00% |
| 2019-12-31 | $144.63 Million | -2.29% |
| 2018-12-31 | $148.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Maravai Lifesciences Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4835500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Maravai Lifesciences Holdings Inc Net Assets Breakdown (December 2025)
Maravai Lifesciences Holdings Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $10.12 Million | 4.76% |
| Common Stock | $2.56 Million | 1.21% |
| Other Comprehensive Income | $524.00K | 0.25% |
| Other Components | $199.18 Million | 93.78% |
| Total Equity | $212.38 Million | 100.00% |
Maravai Lifesciences Holdings Inc Competitors by Market Cap
The table below lists competitors of Maravai Lifesciences Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Evolution Metals & Technologies Corp. Common Stock
NASDAQ:EMAT
|
$1.15 Billion |
|
TTW Public Company Limited
BK:TTW-R
|
$1.15 Billion |
|
He Bei Cheng De LoLo Co Ltd
SHE:000848
|
$1.15 Billion |
|
Norconsult ASA
OL:NORCO
|
$1.15 Billion |
|
Flow Traders BV
AS:FLOW
|
$1.15 Billion |
|
OMH SCIENCE Group Co Ltd
SHE:300486
|
$1.15 Billion |
|
Hunan Valin Wire & Cable Co Ltd
SHE:001208
|
$1.15 Billion |
|
Luoyang Longhua Heat Trans Energy
SHE:300263
|
$1.15 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Maravai Lifesciences Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 325,292,000 to 212,379,000, a change of -112,913,000 (-34.7%).
- Net loss of 130,773,000 reduced equity.
- Other comprehensive income increased equity by 524,000.
- Other factors increased equity by 17,336,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-130.77 Million | -61.58% |
| Other Comprehensive Income | $524.00K | +0.25% |
| Other Changes | $17.34 Million | +8.16% |
| Total Change | $- | -34.71% |
Book Value vs Market Value Analysis
This analysis compares Maravai Lifesciences Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.27x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.76x to 5.27x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $1.62 | $7.72 | x |
| 2019-12-31 | $1.46 | $7.72 | x |
| 2020-12-31 | $0.92 | $7.72 | x |
| 2021-12-31 | $2.59 | $7.72 | x |
| 2022-12-31 | $4.14 | $7.72 | x |
| 2023-12-31 | $3.16 | $7.72 | x |
| 2024-12-31 | $2.36 | $7.72 | x |
| 2025-12-31 | $1.46 | $7.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Maravai Lifesciences Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -61.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -70.41%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 3.63x
- Recent ROE (-61.58%) is below the historical average (4.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -12.28% | -14.32% | 0.23x | 3.74x | $-32.17 Million |
| 2019 | -6.00% | -5.93% | 0.25x | 4.09x | $-22.63 Million |
| 2020 | 86.87% | 27.06% | 0.22x | 14.36x | $68.04 Million |
| 2021 | 57.70% | 22.78% | 0.42x | 6.08x | $150.49 Million |
| 2022 | 40.39% | 24.94% | 0.39x | 4.19x | $165.68 Million |
| 2023 | -28.56% | -41.19% | 0.19x | 3.57x | $-160.70 Million |
| 2024 | -44.53% | -55.89% | 0.26x | 3.10x | $-177.38 Million |
| 2025 | -61.58% | -70.41% | 0.24x | 3.63x | $-152.01 Million |
Industry Comparison
This section compares Maravai Lifesciences Holdings Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $211,904,180
- Average return on equity (ROE) among peers: 1119.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Maravai Lifesciences Holdings Inc (MRVI) | $355.59 Million | -12.28% | 0.70x | $1.15 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $27.43 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $178.43 Million | -42.75% | 0.25x | $241.32 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $15.62 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $155.53K | 11625.26% | 37.80x | $804.31 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.70 Billion |
About Maravai Lifesciences Holdings Inc
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products fo… Read more